人可溶性晚期糖基化终产物受体的原核表达及活性鉴定

摘要/Abstract

摘要： 目的构建人可溶性晚期糖基化终产物受体(hsRAGE)His融合蛋白表达载体并在原核细胞表达与纯化。方法 PCR扩增hRAGE基因编码区的胞质外段,利用分子克隆技术将其重组于pET-14b载体中。利用酶切、序列分析鉴定克隆正确性。转化大肠杆菌BL21(DE)3,用异丙基b-D硫代半乳糖(IPTG)诱导融合蛋白表达。以尿素对获得的包涵体进行处理,用金属螯合亲和层析的方法纯化融合蛋白并进行复性。以Western印迹和ELISA法对融合蛋白的免疫原性及与AGE的结合活性进行鉴定。结果克隆的hsRAGE完全正确,经过表达与纯化,获得了相对分子质量约45000的融合蛋白。纯化得到的变性蛋白经复性后可被相应抗体识别。所得到的hsRAGE具有与AGE相互结合的活性,并能够抑制AGE诱导的内皮细胞NF-kB的表达。结论成功地构建了hsRAGE融合蛋白原核表达载体且获得高效表达,得到大量的复性蛋白;该蛋白具有特异的免疫原性,保持与AGE的结合活性,并能够有效阻断AGE-RAGE相互作用。

Abstract: Objective To construct a eukaryotic expression vector for His-tagged human soluble receptor for advanced glycation end products (hsRAGE),and study the function and biological activity of the fusion protein. Methods The coding sequence of hsRAGE was amplified from the recombinant pCI-neo/RAGE by PCR method.The fragment was cloned into pET-14b vector and identified by digestion with restriction enzymes and sequence analysis.After transformation of the vector into E.coli BL21(DE3),the fusion protein was expressed successfully in response to IPTG induction in the form of inclusion body.After extraction from the bactrerial cells and washing,the fusion protein was dissolved in 8 mol/L urea and purified using immobilized metal ion affinity chromatography.Renaturing of the fusion protein occurred after gradually removal of the denaturants by dialysis.The protein was subsequently identified by Western blotting,enzyme-linked immunosorbent assay (ELISA) and blockade experiments in the endothelial cells. Results The recombinant hsRAGE/pET-14b was verified by enzyme digestion and sequencing.A fusion protein with a molecular weight of about 45 kD was purified,which could interact with anti-RAGE antibody and AGE and block AGE-induced nuclear factor (NF)-kB activation in the endothelial cells. Conclusions His-hsRAGE fusion protein has been cloned,expressed and purified successfully and identified to possess immunogenicity,binding activity to AGE and blocking effect on AGE-RAGE.

中图分类号:

赵善超¹, 姜勇², 刘靖华², 李志杰², 邓鹏², 张桂林¹, 刘志强¹, 张训¹, 侯凡凡¹, 郑少斌¹. 人可溶性晚期糖基化终产物受体的原核表达及活性鉴定[J]. 南方医科大学学报, 2005, 25(07): 769-773.

ZHAO Shan-chao¹, JIANG Yong², LIU Jing-hua², LI Zhi-jie², DENG Peng², ZHANG Gui-lin¹, LIU Zhi-qiang¹, ZHANG Xun¹, HOU Fan-fan¹. Prokaryotic expression and activity identification of recombinant human soluble receptor for advanced glycation end products[J]. Journal of Southern Medical University, 2005, 25(07): 769-773.

参考文献

[1] Hou FF, Jiang JP, Guo JQ, et al. Receptor for advanced glycation end products on human synovial fibroblasts: Role in the pathogenesis of dialysis-related amyloidosis [J]. J Am Soc Nephrol, 2002, 13:1296-130
[2] Katz J, Bhattacharyya I, Farkhondeh-Kish F, et al. Expression of the receptor of advanced glycation end products in gingival tissues of type 2 diabetes patients with chronic periodontal disease: a study utilizing immunohistochemistry and RT-PCR[J]. J Clin Periodontol, 2005, 32 (1): 40-4.
[3] Bartling B, Hofmann HS, Weigle B, et al. Down-regulation of the receptor for advancedglycation end-products (RAGE)supports non-small cell lung carcinoma [J]. Carcinogenesis,2005, 26 (2): 293-301.
[4] Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation endproducts of protein[J]. J Biol Chem, 1992, 267(21): 14998-5004.
[5] 赵善超,侯凡凡,姜勇.晚期糖基化终产物受体的结构和功能[J].生理科学进展,2003,34(1):71-3Zhao SC, Hou FF, Jiang Y. The structure and function of RAGE[J]. Prog Physiol Sci, 2003, 34(1): 71-3.
[6] 朱平,唐磊,赵善超,等.抗人晚期糖基化终产物受体胞外段不同表位单克隆抗体的制备[J].第一军医大学学报,2004,24(2):129-32.Zhu P, Tang L, Zhao SC, et al. Preparation of monoclonal antibodies against different epitopes on extracellular domain of human receptor for advanced glycation end product [J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2004, 24(2): 129-32.
[7] 龚小卫,秦清河,王静珍,等.p38MAPK红色荧光蛋白融合载体的构建及表达[J].第一军医大学学报,2002,22(2):171-3Gong XW, Qin QH, Wang JZ, et al. Construction and expression of red fluorescent protein fusion vector incorporating p38 mitogen- activated protein kinase [J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2002, 22(2): 171-3.
[8] 赵善超,刘靖华,李志杰,等.人晚期糖基化终产物受体胞质内段融合蛋白表达载体的构建与表达[J].第一军医大学学报,2003,23(12):1314-6.Zhao SC, Liu JH, Li ZJ, et al. Vector construction for the intracellular domain of human receptor for advanced glycation end- products and expression of the fusion protein[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao,2003, 23 (12): 1314-6.
[9] Hou FF, Chertow GM, Kay J, et al. Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis [J]. Kidney Int,1997, 51(5): 1514-9
[10] Ernst B, Fortunato S, Dietmar S. Influence of reduced intracellular glutathione availability on the secretion of vasoactive substances by human umbilical vein endothelial cells[J]. Hypertens Pregnancy, 2001, 20 (1): 45-56.
[11] 鄂征.组织培养和分子细胞学技术[M].北京出版社,1999.125-6.
[12] Chavakis T, Bierhaus A, Nawroth PP, et al. RAGE (receptor for advanced glycation end products): a central player in the inflammatory response [J]. Microbes Infect. 2004, 6 (13):1219-25.
[13] Basta G, Lazzerini G, Massaro M, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses [J]. Circulation, 2002, 105 (7):816-22.
[14] Bucciarelli L G, Wendt T, Qu W, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice [J]. Circulation, 2002, 106 (22): 2827-35.
[15] Zeng S, Feirt N, Goldstein M, et al. Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice [J]. Hepatology,2004, 39 (2): 422-32.
[16] Wear-Maggitti K, Lee J, Conejero A, et al. Use of topical sRAGE in diabetic wounds increases neovascularization and granulation tissue formation [J]. Ann Plast Surg,2004, 52(5): 519-21.